Introduction {#sec1}
============

Venous thromboembolism (VTE) is a common clinical vascular syndrome, consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE), which are two different forms of the same disease \[[@B1]\] At present, venous thrombosis has become the third cause of cardiovascular disease and common complications of cancer, such as lung cancer \[[@B2]\]. VTE is a complex multi-factor disease, in which gene mutation plays an important role \[[@B3]\]. However, there are great ethnic and regional characteristics of gene mutation in VTE. Therefore, exploring the susceptible genes to provide the basis for the prevention and treatment of VTE will be one of the important research directions of comprehensive therapy for vascular diseases and cancer.

Methylenetetrahydrofolate reductase (MTHFR) is a homocysteine (Hey) metabolic regulatory enzyme. It could reduce N5, N10-methylene tetrahydro folic acid to N5- methyl tetrahydro folic acid, and the latter has the ability to maintain the stability of plasma Hey. The decrease of MTHFR activity will give rise to impaired Hey methylation and further hyperhomocysteinemia, which could destroy vascular endothelium and change platelet function as well as blood coagulation state, finally participating in the pathogenesis of VTE. Both the mutation of MTHFR gene at 677site from base cytosine (C) to thymine (T) and the mutation of MTHFR gene at 1298site from adenine (A) to cytosine (C) could cause amino acid mistranslation, further decrease MTHFR activity and increase Hey level.

In recent years, many studies about the relationship between MTHFR gene polymorphism and the risk of VTE have been reported, but with inconsistent conclusions. Some hold the view that MTHFR/C677T was a significant risk factor of VTE, which demonstrates the association of MTHFR C677T polymorphism with the susceptibility to VTE \[[@B4]\], but some not \[[@B5]\]. In addition to MTHFR C677T polymorphism, it is also a highly debated issue that whether MTHFR A1298C polymorphism could increase the susceptibility to VTE. Therefore, we conducted this meta-analysis to explore the correlation between MTHFR C677T polymorphism as well as MTHFR A1298C polymorphism and the risk of VTE, providing theoretical basis for the prevention and treatment of VTE.

Materials and methods {#sec2}
=====================

Search strategy and selection criteria {#sec2-1}
--------------------------------------

This systematic review and meta-analysis is reported in accordance with the Preferred Items for Systematic Reviews and Meta-analysis (PRISMA) Statement. Literature was retrieved by formal search of electronic databases (Pubmed, embase, Cochrane library, scopus, OvidSP, Wiley Online library, Springer link, EBSCO, Elsevier Science Direct, Google scholar) without date limitation. To achieve the maximum sensitivity of the search strategy, we used appropriated free text and thesaurus terms including "methylenetetrahydrofolate reductase or MTHFR", "Venous thromboembolism or VTE", "polymorphism or mutation or variant". We also search reference lists of related articles by hand to obtain more studies. The retrieval strategy of Pubmed is as follows: (((((polymorphism\[Title/Abstract\] OR mutation\[Title/Abstract\] OR variant\[Title/Abstract\])) OR "Polymorphism, Genetic"\[Mesh\])) AND ((deep venous thrombosis\[Title/Abstract\]) OR "Venous thromboembolism"\[Mesh\])) AND (((Methylenetetrahydrofolate Reductase (NADPH) or Methylene-THF Reductase (NADPH) or Methylenetetrahydrofolate Reductase or 5,10-Methylenetetrahydrofolate Reductase (NADPH) or Methylene Tetrahydrofolate Reductase or Tetrahydrofolate Reductase, Methylene)) OR "Methylenetetrahydrofolate Reductase (NADPH2)"\[Mesh\]).

Inclusion criteria: (1) Patients with VTE, including venous thrombosis and deep venous thrombosis; (2) Methylenetetrahydrofolate reductase C677T polymorphism and A1298C polymorphism; (3) Sufficient genotype data; (4) *P* value for Hardy--Weinberg equilibrium test \> 0.05; (5) Case--control design.

Data extraction and quality assessment {#sec2-2}
--------------------------------------

Two authors independently extracted the original data. As recommended by the Cochrane Non-Randomized Studies Methods, Newcastle--Ottaw scale (NOS) was used to assess the quality of included researches and a total score of included studies ranging from 7 to 9 was deemed high quality. Disagreement was resolved by discussion. The extracted data were consisted of the follow items: the first author's name, publication year, country, race, genotype distribution data, total number of cases and controls.

Statistical analysis {#sec2-3}
--------------------

Meta-analysis was performed to calculate pooled ORs (Odds ratios) with 95% CI (Confidence interval) by using Review manager 5.3. Heterogeneity among studies was assessed by *I*^2^ statistic. I^2^\> 50% is indicative of heterogeneity \[[@B6]\], random effects model will be used. Otherwise, fixed effect will be implemented. Chi-square distribution was employed to measure the deviation of genotype distribution from Hardy--Weinberg equilibrium in control group. Subgroup analysis was conducted to explore the sources of heterogeneity and the differences between races. We also perform sensitive analysis by changing effect models. Finally, funnel plots were carried out to evaluate publication bias. The *P*-value \<0.05 in all tests was considered significant.

Results {#sec3}
=======

Flowchart and characteristic of including studies {#sec3-1}
-------------------------------------------------

There are 32 eligible studies meeting to our inclusion criteria \[[@B4],[@B5],[@B7]\], including 31 papers for MTHFR C677T polymorphism \[[@B4],[@B5],[@B7],[@B27]\] and 6 papers for MTHFR A1298C polymorphism \[[@B12],[@B15],[@B19],[@B21],[@B26],[@B30]\]. The details of flow diagram for literature selection were shown in [Figure 1](#F1){ref-type="fig"}. Among included studies, a total of 15 for the Asian \[[@B5],[@B8],[@B9],[@B11],[@B13],[@B14],[@B17],[@B18],[@B21],[@B27],[@B34],[@B36]\], mainly in China, and 17 for the Caucasian \[[@B4],[@B7],[@B10],[@B12],[@B15],[@B16],[@B19],[@B20],[@B25],[@B26],[@B28],[@B35]\]. Due to the comprehensive search, the publication year is from 1999 to 2019. The total sample size is nearly 20,000, containing 8223 patients and 10,859 controls. The main features of eligible studies are summarized in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

![Flow diagram for literature selection](bsr-40-bsr20200860-g1){#F1}

###### Characteristics of include studies about MTHFR C677T polymorphism

  Author, year         Country       Race        Case group   Control group   pHWE   NOS                                      
  -------------------- ------------- ----------- ------------ --------------- ------ ------ ------ ------ ----- ------ ------ ---
  Jang, 2013           South Korea   Asian       74           82              47     203    140    203    60    403    0.62   8
  Xu, 2019             China         Asian       42           28              31     101    70     26     24    120    0.10   8
  Yin, 2012            China         Asian       171          157             112    440    182    190    68    440    0.30   7
  Kailibinuer, 2012    China         Asian       22           31              35     88     30     45     11    86     0.65   7
  Wang, 2004           China         Asian       13           28              17     58     19     32     7     58     0.51   7
  Qiu, 2002            China         Asian       23           32              14     69     42     47     12    101    0.98   7
  Hsu, 2001            China         Asian       60           40              7      107    55     44     8     107    0.98   8
  Lu, 2002             China         Asian       18           42              30     90     31     66     46    143    0.73   8
  Guo, 2002            China         Asian       4            26              33     63     16     35     29    80     0.66   7
  Zheng, 2000          China         Asian       12           31              10     53     62     45     15    122    0.34   8
  Lin, 2000            China         Asian       53           50              9      112    76     41     8     125    0.75   7
  He, 2010             China         Asian       15           27              21     63     26     36     13    75     1.00   7
  Li, 2015             China         Asian       71           107             68     246    97     155    40    292    0.21   8
  Gao, 2008            China         Asian       16           34              14     64     14     39     11    64     0.21   7
  Dong, 2013           China         Asian       16           37              15     68     15     41     12    68     0.23   8
  Hsu TS, 2001         China         Asian       48           28              7      83     43     33     6     82     1.00   8
  Karmadonova, 2014    Russia        Caucasian   76           79              19     174    226    201    34    461    0.50   7
  Spiroski, 2008       Macedonia     Caucasian   20           33              10     63     34     35     11    80     0.92   7
  Bezemer, 2007        Netherlands   Caucasian   2044         1891            440    4375   2245   2094   517   4856   0.68   8
  Almawi, 2005         America       Caucasian   80           77              41     198    350    270    77    697    0.08   7
  Miranda, 2002        Netherlands   Caucasian   67           90              14     171    233    186    42    461    0.86   6
  Zalavras, 2002       Greece        Caucasian   70           82              24     176    117    153    30    300    0.14   7
  Amparo, 2010         Spain         Caucasian   14           19              9      42     23     42     14    79     0.79   7
  Tawfik, 2012         Egypt         Caucasian   20           4               25     49     22     1      1     24     0.01   7
  Hanson, 2001         America       Caucasian   58           63              16     137    130    158    41    329    0.80   7
  Ray, 2001            Canada        Caucasian   49           61              19     129    72     44     13    129    0.30   6
  Gerald, 2000         Australia     Caucasian   67           73              15     155    122    141    35    298    0.84   6
  Phillip, 2000        Canada        Caucasian   25           28              12     65     21     35     8     64     0.53   6
  Ben, 2012            Tunisia       Caucasian   20           6               0      26     101    79     17    197    0.96   7
  Kupeli, 2011         Turkey        Caucasian   49           24              7      80     78     26     0     104    0.35   8
  Lupi-Herrera, 2018   Mexico        Caucasian   77           106             29     212    33     54     35    122    0.45   8

pHWE, *P* values for Hardy--Weinberg equilibrium test.

###### Characteristics of include studies about MTHFR A1298C polymorphism

  Author, year        Country     Race        Case group   Control group   pHWE   NOS                                 
  ------------------- ----------- ----------- ------------ --------------- ------ ----- ----- ----- ---- ----- ------ ---
  Hanson, 2001        America     Caucasian   60           62              15     137   164   139   26   329   0.90   8
  Karmadonova, 2014   Russia      Caucasian   67           96              11     174   204   196   49   449   0.98   7
  Martine, 1999       France      Caucasian   65           86              17     168   195   215   46   456   0.49   7
  Li, 2015            China       Asian       163          65              18     246   180   97    15   292   0.92   7
  Ray, 2001           Canada      Caucasian   68           49              12     129   69    49    11   129   0.86   8
  Spiroski, 2008      Macedonia   Caucasian   32           29              2      63    38    39    3    80    0.18   8

pHWE, *P* values for Hardy--Weinberg equilibrium test.

Meta-analysis results {#sec4}
=====================

MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism {#sec4-1}
-------------------------------------------------------------------------

The pooled results suggested that there were significant differences in all models of MTHFR C677T polymorphism, including CC+CT vs TT: OR = 0.68 (0.56, 0.83) ([Figure 2](#F2){ref-type="fig"}), CC vs CT +TT: OR = 0.82 (0.72, 0.94) ([Figure 3](#F3){ref-type="fig"}), CT vs TT: OR = 0.65 (0.52, 0.81) ([Figure 4](#F4){ref-type="fig"}), CC vs TT: OR = 0.73 (0.60, 0.89) ([Figure 5](#F5){ref-type="fig"}) and C vs T: OR = 0.80 (0.71, 0.90) ([Figure 6](#F6){ref-type="fig"}). Due to significant heterogeneity, random effect models were used in all the comparisons. Subgroup analysis showed that, for the Asian, there was no heterogeneity in all the comparisons. But for the Caucasian, no significant association was observed, which tells us the source of heterogeneity and the difference between races ([Table 3](#T3){ref-type="table"}). [Table 4](#T4){ref-type="table"} detailed the results of sensitive analysis, which demonstrated no significant change appeared in all pooled results after the transformation of random effect models into fixed effect models. The funnel plots showed good symmetry bias in all comparisons.

![MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CC+CT vs TT)](bsr-40-bsr20200860-g2){#F2}

![MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CC vs CT+TT)](bsr-40-bsr20200860-g3){#F3}

![MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CT vs TT)](bsr-40-bsr20200860-g4){#F4}

![MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CC vs TT)](bsr-40-bsr20200860-g5){#F5}

![MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (C vs T)](bsr-40-bsr20200860-g6){#F6}

###### Subgroup analysis of the relationship between MTHFR C677T polymorphism and the susceptibility to VTE

  Comparison        Group       OR (95%CI)          *I^2^, P*
  ----------------- ----------- ------------------- ---------------
  **CC+CT vs TT**   Total       0.68 (0.56, 0.83)   69%, \<0.0001
                    Asian       0.54 (0.46, 0.65)   10%, 0.34
                    Caucasian   0.85 (0.63, 1.14)   69%, \<0.0001
  **CC vs CT+TT**   Total       0.82 (0.74, 0.93)   62%, \<0.0001
                    Asian       0.79 (0.66, 0.95)   38%, 0.06
                    Caucasian   0.88 (0.72, 1.07)   71%, \<0.0001
  **CC vs TT**      Total       0.65 (0.52, 0.81)   69%, \<0.0001
                    Asian       0.52 (0.42, 0.65)   19%, 0.24
                    Caucasian   0.81 (0.58, 1.12)   72%, \<0.0001
  **CT vs TT**      Total       0.73 (0.60, 0.89)   61%, \<0.0001
                    Asian       0.56 (0.46, 0.68)   13%,0.31
                    Caucasian   0.93 (0.73, 1.19)   50%, 0.01
  **C vs T**        Total       0.80 (0.71, 0.90)   76%, \<0.0001
                    Asian       0.74 (0.65, 0.83)   41%, 0.04
                    Caucasian   0.88 (0.74, 1.04)   81%, \<0.0001

OR, odds ratio.

###### Sensitive analysis about MTHFR C677T and A1298C Polymorphism and VTE susceptibility

  Comparison         Effect model   OR (95%CI)
  ------------------ -------------- -------------------
  **MTHFR C677T**                   
  CC+CT vs TT        Random         0.68 (0.56, 0.83)
                     Fixed          0.80 (0.73, 0.87)
  CC vs CT+TT        Random         0.82 (0.74, 0.93)
                     Fixed          0.92 (0.87, 0.98)
  CC vs TT           Random         0.65 (0.52, 0.81)
                     Fixed          0.80 (0.73, 0.88)
  CT vs TT           Random         0.73 (0.60, 0.89)
                     Fixed          0.83 (0.75, 0.91)
  C vs T             Random         0.80 (0.71, 0.90)
                     Fixed          0.90 (0.87, 0.95)
  **MTHFR A1298C**                  
  AA+AC vs CC        Random         0.97 (0.71, 1.32)
                     Fixed          0.99 (0.74, 1.33)
  AA vs AC+CC        Random         0.91 (0.77, 1.08)
                     Fixed          0.91 (0.77, 1.08)
  AA vs CC           Random         0.90 (0.66, 1.23)
                     Fixed          0.91 (0.67, 1.25)
  AC vs CC           Random         1.01 (0.67, 1.52)
                     Fixed          1.05 (0.77, 1.43)
  A vs C             Random         0.95 (0.83, 1.07)
                     Fixed          0.95 (0.83, 1.07)

OR, odds ratio.

MTHFR A1298C polymorphism and the susceptibility to VTE {#sec4-2}
-------------------------------------------------------

Similar to C677T polymorphism, the comparisons of five models were conducted. As shown in [Figure 7](#F7){ref-type="fig"}, none of any comparison exhibited significant difference statistically, with AA+AC vs CC: OR = 0.97 (0.71, 1.32) ([Figure 7](#F7){ref-type="fig"}A), AA vs AC +CC: OR = 0.91 (0.77, 1.08) ([Figure 7](#F7){ref-type="fig"}B), AA vs CC: OR = 0.90 (0.66, 1.23) ([Figure 7](#F7){ref-type="fig"}C), AC vs CC: OR = 1.01 (0.67, 1.52) ([Figure 7](#F7){ref-type="fig"}D) and A vs C: OR = 0.95 (0.83,1.07) ([Figure 7](#F7){ref-type="fig"}E). Because of none heterogeneity, fixed effects were adapted. Sensitive analysis also suggested our results were stable ([Table 4](#T4){ref-type="table"}). Publication test failed to be conducted due to small sample included.

![MTHFR A1298C polymorphism and the susceptibility to Venous thromboembolism ((**A**) AA+AC vs CC, (**B**) AA vs AC +CC, (**C**) AA vs CC, (**D**) AC vs CC, (**E**) A vs C)](bsr-40-bsr20200860-g7){#F7}

Discussion {#sec5}
==========

Although some meta-analysis about the relationship between the risk of VTE and MTHFR mutation have been reported, but the objects are mainly limited to C677T and Chinese. We not only expanded the population, including the Asian and Caucasian, but also explored the association of A1298C polymorphism and VTE susceptibility. Our results showed that, in all the comparisons of the gene phenotypic model, MTHFR C677T mutation could increase the risk of VTE in the Asian, but not in the Caucasian. In addition, there may be no association between MTHFR A1298C mutation and VTE susceptibility. Sensitive analysis and publication test suggested that our results were stable and reliable.

The human MTHFR gene, located on lp36.3 and with a cDNA length of 2.2 kb, is composed of 11(12) exons and 10(11) introns. MTHFR plays a key role in folic acid metabolism. The gene sequence of MTHFR is high conserved. If the gene sequence of 677 base cytosine C is mutated to thymine T, the valine generated by the mutation will replace the conserved alanine, which will lead to a serious decrease in the binding ability of MTHFR to flavin adenine dinucleotide \[[@B37]\]. The increased risk of many diseases caused by MTHFR mutation has been reported, such as congenital heart diseases \[[@B38]\], coronary artery disease \[[@B39]\], systemic lupus erythematosus \[[@B40]\] and cancer \[[@B41]\]. MTHFR's thermal stability and enzyme activity were reduced due to the mutant T allele, resulting in hyperhomocysteine, which is an independent risk factor for VTE \[[@B42]\].

Zhang et al. \[[@B43]\] reported T allele, CT genotype, and TT genotype were associated with the risk of VTE in the Chinese population. Similar to our results, a pooled study of three Asian populations also showed the TT homozygous genotype could increase and the susceptibility to VTE \[[@B17]\]. Den et al. \[[@B44]\] reported that, in non-north American populations, the mutant T allele increased the risk of VTE compared with the wild-type C allele, but not in north American populations. The reason may be that higher intake of folic acid and riboflavin in north American populations reduces the risk of high homocysteine in carriers of the mutant T allele. Our study demonstrated that, regardless of gene models, C677T mutation couldn't increase VTE susceptibility in the Caucasian.

1298 site of MTHFR is located in the exon 7 and encodes regulatory region of s-adenosine methionine. Likewise, the mutation of adenine (A) to cytosine (C) in this site causes glutamate to be replaced by alanine, decreasing the phosphorylation of serine and cysteine and thus affecting the expression of MTHFR as well \[[@B45]\]. As another MTHFR gene mutation, the relationship between MTHFR A1298C polymorphism and the risk of disease is also explored, such as Alzheimer's disease \[[@B46]\] and lung cancer \[[@B47]\]. Our study is the first meta-analysis to explore the relationship between MTHFR A1298C polymorphism and VTE susceptibility. Six studies were included, in which only one paper was from the Asian, so we didn't conduct subgroup analysis and publication test. Finally, no significant association was observed in any comparison of all gene models.

Because of the comprehensive search, large samples were included. Subgroup analysis suggested race is the source of heterogeneity and there exists great difference between the Asian and Caucasian. Of course, there were some limitation we need point out. Owe to insufficient data provided, confounding factors, including age, gender, body mass index, smoking status, drink abuse and other environmental factors, are difficult to fully be adjusted. Then, the controls were not uniformly defined, such as population- and hospital-based controls, and the latter may not necessarily be representative of the underlying source population.

In conclusions, our study uncovered that MTHFR C677T polymorphism may increase susceptibility to VTE in the Asian, but not in the Caucasian. There may be no association between MTHFR A1298C polymorphism and VTE. Our conclusion requires further focus on the effect of gene--gene and gene--environment interaction as well as different VTE types.
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